VEGFA and leukemia: This has shown particularly advantageous for quenching the convex VEGF epitope, which is likely inaccessible by helical‐scaffolds, hitherto the most‐used scaffolds for de novo binders.[52] Selected VEGF binders could inhibit the VEGF‐dependent proliferation of leukemia cells, as well as the survival of primary human endothelial cells.